Matches in SemOpenAlex for { <https://semopenalex.org/work/W1576880551> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W1576880551 endingPage "468" @default.
- W1576880551 startingPage "465" @default.
- W1576880551 abstract "Moxonidine is centrally acting imidazoline type-1 receptor agonist that significantly lowers blood pressure and has some insulin-sensitising actions. Its effects on plasma lipid profiles are uncertain. This study examined the effects of moxonidine on detailed lipid and lipoprotein profiles in 12 patients with hypertension and type 2b Fredricksen hyperlipidaemia. Treatment with moxonidine in six patients who completed the study resulted in a 10/5 mmHg reduction in 24-h ambulatory blood pressure (p = 0.01). A significant reduction in total and low-density-lipoprotein cholesterol (LDL-C) of 10% (p = 0.04) and 18% (p = 0.03), respectively, was seen. Triglycerides were reduced non-significantly by 23%, and high-density-lipoprotein cholesterol (HDL-C) was increased by 16%. There were no significant changes in apolipoprotein (apo) A-1 and B concentrations. No significant shifts were seen in HDL-C, LDL-C, very-low-density-lipoprotein cholesterol (VLDL-C) or apolipoprotein peak positions with therapy. Analysis of area under curve for each subfraction showed that moxonidine therapy resulted in a redistribution within the apoB profile. A slight non-significant reduction in VLDL apoB was seen. There was a reduction in the dense LDL apoB peak (p = 0.02) but less in the buoyant LDL apoB peak (p = 0.17) with a countervailing increase in LDL-C in the buoyant fraction (p = 0.01). The HDL-C and apoA-1 profile showed a shift from dense HDL apoA-1 (p = 0.01) to a buoyant HDL apoA-1sub-species (p = 0.01). These changes are consistent with a tendency for moxonidine to improve atherogenic lipid and lipoprotein profiles by actions on insulin-sensitisation and possibly through a direct cholesterol-reducing effect as seen with other imidazoles." @default.
- W1576880551 created "2016-06-24" @default.
- W1576880551 creator A5007856802 @default.
- W1576880551 creator A5009077811 @default.
- W1576880551 creator A5036630941 @default.
- W1576880551 creator A5066079193 @default.
- W1576880551 date "2004-05-28" @default.
- W1576880551 modified "2023-09-23" @default.
- W1576880551 title "Effect of moxonidine on lipid subfractions in patients with hypertension" @default.
- W1576880551 cites W1971179523 @default.
- W1576880551 cites W1979587242 @default.
- W1576880551 cites W1994166619 @default.
- W1576880551 cites W1996146831 @default.
- W1576880551 cites W2046158926 @default.
- W1576880551 cites W2083992047 @default.
- W1576880551 cites W2094667354 @default.
- W1576880551 cites W2136647159 @default.
- W1576880551 cites W2160234571 @default.
- W1576880551 doi "https://doi.org/10.1111/j.1368-5031.2004.00158.x" @default.
- W1576880551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15206502" @default.
- W1576880551 hasPublicationYear "2004" @default.
- W1576880551 type Work @default.
- W1576880551 sameAs 1576880551 @default.
- W1576880551 citedByCount "18" @default.
- W1576880551 countsByYear W15768805512013 @default.
- W1576880551 countsByYear W15768805512016 @default.
- W1576880551 countsByYear W15768805512017 @default.
- W1576880551 countsByYear W15768805512018 @default.
- W1576880551 countsByYear W15768805512019 @default.
- W1576880551 countsByYear W15768805512021 @default.
- W1576880551 countsByYear W15768805512022 @default.
- W1576880551 crossrefType "journal-article" @default.
- W1576880551 hasAuthorship W1576880551A5007856802 @default.
- W1576880551 hasAuthorship W1576880551A5009077811 @default.
- W1576880551 hasAuthorship W1576880551A5036630941 @default.
- W1576880551 hasAuthorship W1576880551A5066079193 @default.
- W1576880551 hasConcept C126322002 @default.
- W1576880551 hasConcept C134018914 @default.
- W1576880551 hasConcept C170493617 @default.
- W1576880551 hasConcept C2777014715 @default.
- W1576880551 hasConcept C2778163477 @default.
- W1576880551 hasConcept C2778270857 @default.
- W1576880551 hasConcept C2778938600 @default.
- W1576880551 hasConcept C2780072125 @default.
- W1576880551 hasConcept C62746215 @default.
- W1576880551 hasConcept C71924100 @default.
- W1576880551 hasConcept C8243546 @default.
- W1576880551 hasConceptScore W1576880551C126322002 @default.
- W1576880551 hasConceptScore W1576880551C134018914 @default.
- W1576880551 hasConceptScore W1576880551C170493617 @default.
- W1576880551 hasConceptScore W1576880551C2777014715 @default.
- W1576880551 hasConceptScore W1576880551C2778163477 @default.
- W1576880551 hasConceptScore W1576880551C2778270857 @default.
- W1576880551 hasConceptScore W1576880551C2778938600 @default.
- W1576880551 hasConceptScore W1576880551C2780072125 @default.
- W1576880551 hasConceptScore W1576880551C62746215 @default.
- W1576880551 hasConceptScore W1576880551C71924100 @default.
- W1576880551 hasConceptScore W1576880551C8243546 @default.
- W1576880551 hasIssue "5" @default.
- W1576880551 hasLocation W15768805511 @default.
- W1576880551 hasLocation W15768805512 @default.
- W1576880551 hasOpenAccess W1576880551 @default.
- W1576880551 hasPrimaryLocation W15768805511 @default.
- W1576880551 hasRelatedWork W1576880551 @default.
- W1576880551 hasRelatedWork W1976602105 @default.
- W1576880551 hasRelatedWork W1998026951 @default.
- W1576880551 hasRelatedWork W1999568358 @default.
- W1576880551 hasRelatedWork W2025648868 @default.
- W1576880551 hasRelatedWork W2026539275 @default.
- W1576880551 hasRelatedWork W2117255531 @default.
- W1576880551 hasRelatedWork W2129790693 @default.
- W1576880551 hasRelatedWork W2157155183 @default.
- W1576880551 hasRelatedWork W2413861530 @default.
- W1576880551 hasVolume "58" @default.
- W1576880551 isParatext "false" @default.
- W1576880551 isRetracted "false" @default.
- W1576880551 magId "1576880551" @default.
- W1576880551 workType "article" @default.